BioAge Labs (BIOA) Stock Price, News & Analysis

Company Overview

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets. The company has assembled a diversified pipeline of preclinical and early-stage clinical programs spanning immuno-oncology, inflammatory diseases, metabolic disorders and fibrotic conditions. Its lead programs are advancing through proof-of-concept studies designed to demonstrate the potential to modulate age-related pathways and produce durable clinical benefits.

Founded in 2015 and headquartered in South San Francisco, California, BioAge Labs operates a research and development facility in the San Francisco Bay Area and collaborates with academic institutions and contract research organizations worldwide. Since its inception, the company has secured multiple partnerships to expand its target discovery efforts and accelerate translational research. BioAge completed its public listing via merger with a special purpose acquisition company in early 2021, positioning it to fund ongoing clinical development and platform expansion.

BioAge is led by President and Chief Executive Officer Michael A. Duncan, who brings extensive experience in biotech leadership, strategic partnerships and capital markets. The company’s scientific strategy is guided by co-founder and Chief Scientific Officer Kristen Fortney, Ph.D., along with a management team experienced in drug discovery, clinical development and regulatory affairs. Together, they aim to translate aging biology insights into medicines that improve health outcomes for aging populations.

Key Stats

• Today's Range: $14.73 to $16.62
• 50-Day Range: $15.34 to $21.55
• 52-Week Range: $3.79 to $24.00
• Volume: 520,130 shs
• Average Volume: 393,579 shs
• Market Capitalization: $727.65 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $45.00
• Consensus Rating: Moderate Buy

BioAge Labs Stock Analysis - MarketRank™

BioAge Labs scored higher than 59% of companies evaluated by MarketBeat, and ranked 33rd out of 80 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

BioAge Labs has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on no strong buy ratings, 5 buy ratings, no hold ratings, and 1 sell rating.

Upside Potential

BioAge Labs has a consensus price target of $45.00, representing about 174.9% upside from its current price of $16.37.

Amount of Analyst Coverage

BioAge Labs has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioAge Labs are expected to grow in the coming year, from ($2.59) to ($2.41) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioAge Labs is -6.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioAge Labs is -6.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioAge Labs has a P/B Ratio of 1.92. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.36% of the float of BioAge Labs has been sold short.

Short Interest Ratio / Days to Cover

BioAge Labs has a short interest ratio ("days to cover") of 4.38.

Change versus previous month

Short interest in BioAge Labs has recently increased by 7.97%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioAge Labs does not currently pay a dividend.

Dividend Growth

BioAge Labs does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 0.43

News Sentiment

BioAge Labs has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Manufacturing companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for BioAge Labs this week, compared to 3 articles on an average week.

Search Interest

1 people have searched for BIOA on MarketBeat in the last 30 days.

MarketBeat Follows

2 people have added BioAge Labs to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioAge Labs insiders have not sold or bought any company stock.

Percentage Held by Insiders

20.82% of the stock of BioAge Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

BioAge Labs has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/08/2026
• Today: 5/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Manufacturing
• Industry: N/A
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BIOA
• Previous Symbol: NYSE:BIOA
• CIK: 1709941
• Web: N/A
• Phone: (510) 806-1445
• Fax: N/A
• Employees: N/A
• Year Founded: 2015

Price Target and Rating

• Average Price Target for BioAge Labs: $45.00
• High Price Target: $60.00
• Low Price Target: $23.00
• Potential Upside/Downside: +174.9%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.67
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.40)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$80.61 million
• Net Margins: -871.75%
• Pretax Margin: -871.75%
• Return on Equity: -29.40%
• Return on Assets: -27.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 24.76
• Quick Ratio: 24.76

Sales & Book Value

• Annual Sales: $8.99 million
• Price / Sales: 80.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.53 per share
• Price / Book: 1.92

Miscellaneous

• Outstanding Shares: 44,450,000
• Free Float: 35,198,000
• Market Cap: $727.65 million
• Optionable: N/A
• Beta: 0.99